Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 2
1(20.0%)
5Total
N/A(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06479304Not ApplicableRecruiting

The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP

Role: collaborator

NCT06479317Not ApplicableRecruiting

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

Role: collaborator

NCT06479291Not ApplicableRecruiting

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

Role: collaborator

NCT04506281Phase 2Unknown

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT02897713Not ApplicableSuspended

Feasibility, Safety, and Outcomes of Intensive Enteral Nutrition in Patients With Mechanical Ventilation

Role: collaborator

All 5 trials loaded